10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. cut its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 47.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 87,590 shares of the company’s stock after selling 79,904 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in 10x Genomics were worth $4,902,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of TXG. FMR LLC lifted its holdings in shares of 10x Genomics by 56.4% during the third quarter. FMR LLC now owns 12,666,998 shares of the company’s stock worth $522,514,000 after purchasing an additional 4,565,400 shares during the period. BlackRock Inc. lifted its holdings in 10x Genomics by 14.2% in the first quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock valued at $696,572,000 after acquiring an additional 1,138,358 shares during the period. ARK Investment Management LLC lifted its holdings in 10x Genomics by 35.0% in the fourth quarter. ARK Investment Management LLC now owns 4,041,287 shares of the company’s stock valued at $226,150,000 after acquiring an additional 1,047,827 shares during the period. Millennium Management LLC lifted its holdings in 10x Genomics by 467.3% in the fourth quarter. Millennium Management LLC now owns 1,213,394 shares of the company’s stock valued at $44,216,000 after acquiring an additional 999,487 shares during the period. Finally, Norges Bank acquired a new stake in 10x Genomics in the fourth quarter valued at $32,616,000. 84.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Stifel Nicolaus reduced their target price on 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a report on Friday, February 16th. Barclays reduced their target price on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, April 10th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $60.88.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 2,821 shares of 10x Genomics stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $130,725.14. Following the completion of the sale, the chief executive officer now owns 847,560 shares in the company, valued at approximately $39,275,930.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other 10x Genomics news, CEO Serge Saxonov sold 2,821 shares of 10x Genomics stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $130,725.14. Following the completion of the sale, the chief executive officer now owns 847,560 shares in the company, valued at approximately $39,275,930.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Justin J. Mcanear sold 1,865 shares of 10x Genomics stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total value of $86,424.10. Following the completion of the transaction, the chief financial officer now directly owns 95,240 shares in the company, valued at $4,413,421.60. The disclosure for this sale can be found here. Insiders sold 12,959 shares of company stock worth $592,806 in the last 90 days. 10.65% of the stock is owned by company insiders.

10x Genomics Stock Performance

Shares of TXG stock opened at $32.86 on Tuesday. The business has a fifty day simple moving average of $41.22 and a 200-day simple moving average of $43.28. 10x Genomics, Inc. has a fifty-two week low of $32.68 and a fifty-two week high of $63.57.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, February 15th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). The company had revenue of $183.98 million for the quarter, compared to analysts’ expectations of $182.73 million. 10x Genomics had a negative return on equity of 28.82% and a negative net margin of 41.17%. The company’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.15) EPS. On average, sell-side analysts expect that 10x Genomics, Inc. will post -1.47 EPS for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.